The first‐in‐human Phase 1 clinical trial, known as The ANQUR study (NCT05633459), has commenced to assess the safety, tolerability, and pharmacokinetics of QRL‐20 in patients with ALS without SOD1 and FUS mutations, aiming to rescue STMN2 expression. Here, STMN2 is linked to amyotrophic lateral sclerosis.